Today at the International Congress of Parkinson’s Disease & Movement Disordersâ, Global Kinetics, the global leader in precision medicine and digital therapeutics for persons with neurological movement disorders, announced it has rebranded as PKG Health. The effort includes the brand, new logo, refreshed visual identity and updated web site.
“Most of our customers and partners know us as the PKG company,” said Zach Henderson, PKG Health CEO. “From patients to clinicians to life science partners, there is tremendous brand equity in ‘PKG’ in the neurology space because of the extensive clinical evidence we’ve built.”
The Melbourne, Australia headquartered business with a clinical presence in over 20 countries globally including the US and most of Europe, is backed by international investment firms such as Brandon Capital, Bioscience Managers, Korean Investment Partners, Riyadh Valley Company, among others.
“The FDA cleared Class II PKG system and industry leading algorithms have evolved dramatically in recent years, now covering the spectrum of precision medicine across the product life cycle supporting clinical trials, commercialization and enabling objective measurement, adjustment and escalation of therapies within clinical care,” shared Dr. Yuri Maricich, recently appointed Chief Medical & Scientific Officer and digital therapeutics veteran.
“We’re excited to unveil updated branding that more accurately reflects the evolution of the platform we are offering, which is the leader in precision medicine in the neurology space,” concluded Mr. Henderson.
PKG Health leverages the world’s largest body of clinical evidence in neurology, to create and deliver precision medicine by accelerating the research, approval and adoption of treatments. Because we believe every person with a neurological condition deserves to live their best life every day. For more information on PKG Health, please visit us at www.pkghealth.com.
